Pilot study of (68)Ga-DOTA-F(ab′)(2)-trastuzumab in patients with breast cancer

OBJECTIVE: (68)Ga-1,4,7,10-Tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (DOTA)-F(ab′)(2)-trastuzumab [(68)Ga-DOTA-F(ab′)(2)-trastuzumab] has been developed at our institution as a positron imaging reagent for assessing human epidermal growth factor receptor 2 (HER2) expression status by in-v...

Descripción completa

Detalles Bibliográficos
Autores principales: Beylergil, Volkan, Morris, Patrick G., Smith-Jones, Peter M., Modi, Shanu, Solit, David, Hudis, Clifford A., Lu, Yang, O’Donoghue, Joseph, Lyashchenko, Serge K., Carrasquillo, Jorge A., Larson, Steven M., Akhurst, Timothy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815146/
https://www.ncbi.nlm.nih.gov/pubmed/24100444
http://dx.doi.org/10.1097/MNM.0b013e328365d99b

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815146/
https://www.ncbi.nlm.nih.gov/pubmed/24100444
http://dx.doi.org/10.1097/MNM.0b013e328365d99b

Ejemplares similares